BioLineRx (NASDAQ:BLRX) Issues Earnings Results, Beats Estimates By $0.07 EPS

BioLineRx (NASDAQ:BLRX) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07, Zacks reports. The firm had revenue of $4.80 million during the quarter, compared to analysts’ expectations of $0.17 million. During the same quarter in the prior year, the firm earned ($0.09) EPS.

BioLineRx Price Performance

Shares of NASDAQ BLRX traded up $0.01 during trading on Friday, hitting $1.12. 163,193 shares of the company were exchanged, compared to its average volume of 342,065. The company has a market cap of $81.13 million, a price-to-earnings ratio of -1.24 and a beta of 1.40. BioLineRx has a 1 year low of $0.81 and a 1 year high of $2.53. The firm’s fifty day moving average price is $1.20 and its 200 day moving average price is $1.46. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.53 and a quick ratio of 1.86.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. StockNews.com raised shares of BioLineRx to a “sell” rating in a report on Wednesday. HC Wainwright reissued a “buy” rating and set a $21.00 price objective on shares of BioLineRx in a report on Tuesday.

Institutional Investors Weigh In On BioLineRx

Several institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC boosted its position in shares of BioLineRx by 49.1% in the 3rd quarter. Renaissance Technologies LLC now owns 68,222 shares of the biotechnology company’s stock worth $63,000 after buying an additional 22,478 shares in the last quarter. LPL Financial LLC boosted its position in shares of BioLineRx by 152.7% in the 4th quarter. LPL Financial LLC now owns 117,710 shares of the biotechnology company’s stock worth $69,000 after buying an additional 71,134 shares in the last quarter. Envestnet Asset Management Inc. purchased a new stake in shares of BioLineRx in the 1st quarter worth about $88,000. Finally, Atria Wealth Solutions Inc. purchased a new stake in shares of BioLineRx in the 1st quarter worth about $178,000. 1.56% of the stock is currently owned by hedge funds and other institutional investors.

About BioLineRx

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.